Compare Global X Autonomous & Electric Vehicles (DRIV) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Neurocrine Biosciences Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.8 (market cap $356.37M), while Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 40.3× Global X Autonomous & Electric Vehicles's market cap, and Global X Autonomous & Electric Vehicles is more actively traded (22,397 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DRIV | NBIX | |
|---|---|---|
Market Cap | $356.37M | $14.36B |
Volume | 22,397 | 1,237,180 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $185.50 |
52-Week Low | $27.58 | $123.10 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $33.37, down 1.68% today amid mixed technical signals. The overall technical outlook is bullish with neutral oscillators, while key support sits at $33. Recent news highlights automotive sector focus on hybrid and electric vehicles, though company-specific financial ratios are currently unavailable for analysis.
The stock shows technical resilience near support levels with bullish momentum indicators. Investment appeal hinges on forthcoming financial disclosures and sector trends favoring EV/hybrid adoption. Key risks include sector competition and reliance on broader automotive market performance without current fundamental data.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
